Uppsala-based DexTech are now preparing for the proof-of-concept study that will evaluate the drug candidate OsteoDex for the treatment of multiple myeloma. The candidate has shown clear clinical efficacy results in castration-resistant prostate cancer and preclinical indications of efficacy also in multiple myeloma. BioStock took closer look at the multiple myeloma treatment market to identify the potential of DexTech's complementary venture.